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Abstract
Background: Duchenne musclar dystrophy (DMD) is an X-linked recessive disease caused by
mutations of dystrophin gene, there is no effective treatment for this disorder at present. Plasmid-
mediated gene therapy is a promising therapeutical approach for the treatment of DMD. One of
the major issues with plasmid-mediated gene therapy for DMD is poor transfection efficiency and
distribution. The herpes simplex virus protein VP22 has the capacity to spread from a primary
transduced cell to surrounding cells and improve the outcome of gene transfer. To improve the
efficiency of plasmid-mediated gene therapy and investigate the utility of the intercellular trafficking
properties of VP22-linked protein for the treatment for DMD, expression vectors for C-terminal
versions of VP22-microdystrophin fusion protein was constructed and the VP22-mediated shuttle
effect was evaluated both in vitro and in vivo.
Results: Our results clearly demonstrate that the VP22-microdystrophin fusion protein could
transport into C2C12 cells from 3T3 cells, moreover, the VP22-microdystrophin fusion protein
enhanced greatly the amount of microdystrophin that accumulated following microdystrophin gene
transfer in both transfected 3T3 cells and in the muscles of dystrophin-deficient (mdx) mice.
Conclusion: These results highlight the efficiency of the VP22-mediated intercellular protein
delivery for potential therapy of DMD and suggested that protein transduction may be a potential
and versatile tool to enhance the effects of gene delivery for somatic gene therapy of DMD.
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Duchenne muscular dystrophy (DMD) is a lethal x-linked
genetic disease characterized by progressive skeletal mus-
cle degeneration, occuring in one in 3500 male live births
[1]. DMD results from mutation in the dystrophin gene,
leading to the absence of a functional dystrophin protein
and loss of the dystrophin-glycoprotein complex (DGC),
which together render the sarcolemmal membrane sus-
ceptible to mechanical injury [2,3]. These deficiencies in
turn lead to chonic muscle fiber necrosis and diffuse wast-
ing, with muscle weakness appearing in childhood, fol-
lowed by severe parallesis in adolescence, and death in the
20 s [1]. In spite of the progress made in orthopedic, res-
piratory, and cardiac management of patients, there
remains no effective treatment for this disease.
Replacing and/or repairing the mutated dystrophin gene
by full-length or truncated versions of dystrophin is an
attractive approach that may offer a treatment for DMD.
Gene transfer of dystrophin into skeletal muscle has been
accomplished by intramuscular or intravenous/arterial
injection of a therapeutic plasmid [4-8] or viral vector [9-
12]. Due to the potential for immune responses, the lim-
ited carrying capacity of viral vectors and the difficulty in
specifically targeting muscles bodywide, viral vector-
mediated DMD gene therapy needs more improvements
before demonstrating clinical utility [13]. The simplest
form of gene therapy is the direct injection plasmid DNA
into skeletal muscle. Direct injection of plasmid DNA into
mdx mice though intramuscular or intravenous/arterial
injection can result in expression of dystrophin in up to
10% of the muscle fibers, leading to a decrease in the per-
centage of myofibers displaying central nucleation [4-8].
In a phase I clinical trial, nine patients were injected intra-
muscularly with a plasmid-vector encoding a dystrophin
cDNA, and dystrophin expression was detected in six
patients without any adverse effects [14]. These results are
encouraging for the further development of this method,
however, the poor transfection efficiency for plasmid-
mediated gene therapy is still a problem, especially with a
systemic muscle disease such as DMD. Thus, enhanced
expression and increased production and distribution of
dystrophin are likely to be important developments for
plasmid-mediated gene therapy for DMD.
Recently, a class of proteins known as cell-penetrating
peptides were reported that had the capacity to deliver
their cargo molecules across plasma membrane bilayers
and translocate into neighboring cells, thereby increasing
intracellular delivery of various cargoes with molecular
masses several times greater than their own. These pro-
teins may enhance the low transduction efficiency typi-
cally obtained with plasmid-mediated gene therapy, and
they include the Tat (transactivator of transcription) pro-
tein of human immunodeficiency virus (HIV)[15,16], the
antennapedia homeodomain proteins (AntPs) of Dro-
sophila melanogaster and other species [17,18], and VP22
of herpes simplex virus (HSV) [19]. Many experiments
have demonstrated that VP22 can enhance intercellular
trafficking of proteins fused to its N- or C-terminus in vitro
and in vivo [20-26]. Moreover, VP22-fusion proteins
retained both VP22-mediated transport properties and the
biophysiological functions of the linked passenger pro-
teins, enhancing the therapeutic effects of transduced
genes and proteins. This property has been observed with
VP22-linked p27, p53, CD and E2 for delivery to tumors
[20-23], VP22-GFP following adenovirus-mediated trans-
gene delivery to CNS neurons [24], and VP22-mediated
intercellular protein delivery was useful in enhancing the
efficacy of myocardial gene therapy [25]. VP22-lacZ trans-
fection resulted in higher amounts of protein expression
compared with lacZ transfection. Preclinical evaluation
using the TK-VP22 fusion revealed an enhanced cytotoxic-
ity in vitro and in vivo using mixed populations of wild-
type and expressing cells [27-29]. However, there have
been no reports about the application of protein transduc-
tion to Duchenne muscular dystrophy therapy. Here, we
studied the translocation properties of the VP22 protein
fused to a microdystrophin cDNA for potential therapy of
DMD. We demonstrated that the HSV-1-derived VP22
protein enhanced microdystrophin protein accumulation
in vitro and in vivo. Therefore, VP22 may be a potent and
versatile tool to enhance the effectiveness of somatic gene
therapy for DMD.
Results
VP22 mediated intercellular trafficking of microdystrophin 
fusion proteins in vitro
To determine whether the VP22-microdystrophin fusion
proteins were able to spread from a primary expressing
cell into neighboring cells, NIH 3T3 cells were transfected
with 3.0 µg of the expression plasmids pAVP22, pAM-
ICDYS, or pAVP22-MICDYS. 48 h post-transfection, indi-
rect immunofluorescen -ce was performed. As shown in
Fig. 1, in the wells transfected with pAMICDYS approxi-
mately 10% of cells were microdystrophin-positive after
48 h transfected; however, 47% of cells transfected with
pAVP22-MICDYS were microdystrophin-positive, repre-
senting a 370% increase in the number of cells that con-
tained microdystrophin protein. Following collection
with the media supernatant and transfer onto the C2C12
myotubes to analyze whether HSV-VP22 is able to carry
microdystrophin into C2C12 cells, indirect immunofluo-
rescence was performed to detect the expression of micro-
dystrophin after 45 min transfection (Fig. 1). As shown in
Fig. 1D, some microdystrophin proteins were detected in
C2C12 cells transfected by supernatant with pAVP22-
MICDYS, the results clearly demonstrated that VP22 could
transport the VP22-microdystrophin fusions from the pri-
mary infected cells (3T3 cells) into the C2C12 cells.Page 2 of 9
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distribution in TA of mdx mice
To determine whether VP22 could enhance microdys-
trophin protein expression and whether the VP22-micro-
dystrophin fusion proteins were able to spread in muscles
of mdx mice, the plasmids pAMICDYS and pAVP22-
MICDYS were injected intramuscularly into the TA mus-
cles, and the expression of microdystrophin were tested by
immunocytochemistry 2 weeks and 16 weeks post-injec-
tion and Western-blotting 2 weeks post-injection. As
shown in Fig. 2A, microdystrophin-positive fibers per
cross-section injected with pAVP22-MICDYS were mark-
edly greater than that injected with pAMICDYS, moreover,
there was no evidence of inflammation in the TA. How-
ever, there was a slight decline of microdystrophin-posi-
tive fibers in the TA from 2 weeks to 16 weeks after
plasmids injection (Fig. 2B). Western-blotting analysis of
microdystrophin gene expression was performed after 2
weeks following injection with equal dosage either pAM-
CIDYS or pAVP22-MICDYS (Fig. 3). Semiquantitative
analysis of band intensity demonstrated that the expres-
sion of VP22-linked microdystrophin following pAVP22-
MICDYS transfection was 3.1-fold greater than that of
microdystrophin following pAMICDYS transfection. The
number of microdystrophin-positive fibers per cross-sec-
tion injected with pAVP22-MICDYS were significantly
increased when compared to muscle of injected with
pAMCIDYS. The average number of microdystrophin-
positive fibers in each TA injected with pAVP22-MICDYS
was about 2.3-times higher than that of TA injected with
pAMCIDYS after 2 weeks (Table 1). Thus, VP22 fusion
proteins increased the area containing dystrophin-posi-
tive muscle fibers to span almost all the left TA muscles
and more than tripled the total number of TA myofibers
transduced following a single microdystrophin injection.
VP22-mediated microdystrophin gene expression is more 
efficient in correcting central nucleation in mdx muscle
Muscles of mdx mice are characterized by the presence of
abundant central nuclei in myofibers, and previous stud-
ies have demonstrated that transgenic expression of the
microdystrophin in mdx mice remarkably ameliorated
mdx mouse skeletal muscle pathology and the percentage
of central nucleation was reduced to less than 1% in both
limb muscle and the diaphragm, AAV-mediated microd-
ystrophin expression also reduced central nucleation from
70% to 14% in 7-week-old mdx mice [30]. To further
investigate whether fusion with VP22 can enhance micro-
dystrophin spread, the degree of central nucleation in
myofibers was monitored following injection of plasmid
expressing VP22-microdystrophin or VP22 alone. HE
staining evaluated the amelioration of muscle pathology
(Fig. 4). Compared with contralateral muscles of mdx
mice treated by PBS, the extent of central nucleation of
mdx TA muscles injected with pAMICDYS was reduced
from 77 ± 5% to 38 ± 3% (2 weeks post-injection) and 86
± 4% to 43 ± 4% (16 weeks post-injection). However,
compared with contralateral muscles of mdx mice treated
by PBS, the number of centrally-located nuclei in pAVP22-
MICDYS transduced TA muscles were significantly
reduced from 77 ± 5% to 9 ± 2% (2 weeks post-injection)
and 86 ± 4% to 14 ± 3% (16 weeks post-injection) (Fig.
5). These results indicated that spread of the microdys-
trophin fusion protein could retard significantly the
degeneration of muscle in young mdx mice. Furthermore,
VP22 enhanced the spread of microdystrophin and was
more effective in reducing the number of centrally nucle-
ated myofibers.
Table 1: Quantitative analysis the numbers of microdystrophin-
positive fibers of TA injected by pAMICDYS or pAVP22-
MICDYS after 2 weeks
N Number of microdystrophin-
postive fibers (SD ± mean)
Percent of 
total fibers
Control 8 2 ± 1 < 1%
pAMICDYS 10 64 ± 27 14 ± 3%
pAVP22-MICDYS 10 139 ± 32 32 ± 5%
N, Number of muscles used for the analysis in each group.
*, Significant different compared to pAMICDYS, p < 0.05.
Intercellular trafficking of VP22-MICDYS in the transfected C2C12 cellsFigur 1
Intercellular trafficking of VP22-MICDYS in the 
transfected C2C12 cells. 3T3 cells were transfected with 
the plasmid pAMICDYS (A), pAVP22-MICDYS (B), pAVP22 
(C) respectively. 48h post-transfection, transfected cells 
were fixed and immunocytochemistry was performed with 
the monoclonal anti-dystrophin Amino Terminal. Magnifica-
tion: × 100. At 48 h after transfection with pAVP22, pAM-
ICDYS, pAVP22-MICDYS, cell supernatant were prepared 
from 3T3 cells and then added to C2C12 cells in a 35 mm 
dish. After 45 min, the cells were washed with PBS and proc-
essed for immunocytochemistry. (D) Transfected by super-
natant with pAMICDYS; (E) Transfected by supernatant with 
pAVP22-MICDYS. Magnification: × 200.Page 3 of 9
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VP22-mediated microdystrophin gene expression was more efficient in reducing central nucleation in mdx miceFigure 4
VP22-mediated microdystrophin gene expression 
was more efficient in reducing central nucleation in 
mdx mice. Histological analysis the left TA of mdx mice 
injected by pAMICDYS, pAVP22-MICDYS and the right TA 
injected by PBS. Shown are H&E-stained TA muscle cross 
sections from post-injection 2 weeks (A, B, C), post-injection 
16 weeks (D, E, F). The left TA muscles treated by pAM-
ICDYS (B, E), pAVP22-MICDYS (C, F); the right TA muscles 
treated by PBS (A, D). Magnification: × 200. Centrally nucle-
ated fibers were counted in transverse H&E cryosections 
from treated mdx mice. The ratio of centrally nucleated fib-
ers (%) is shown as means ± SE in TA muscle at post-injec-
tion 2 weeks (G) and 16 weeks (H). * p < 0.05 compared 
with mdx mice; +p < 0.05 compared with pAMICDYS trans-
fered mice.
VP22 enhanced microdystrophin gene expression and distri-bution in mdx miceFigur  2
VP22 enhanced microdystrophin gene expression 
and distribution in mdx mice. (A) The effect of VP22 was 
reflected in the level of microdystrophin expression in pAM-
ICDYS (a) and pAVP22-MICDYS (b) injected the left TA 
muscles. Microdystrophin -positive fibers were detected in 
both groups, but the number of microdystrophin-positive fib-
ers and the intensity of immunofluorescence were uniformly 
greater in pAVP22-MICDYS injected TA muscles. Magnifica-
tion: × 100. (B) Immunostaining analysis microdystrophin 
expression in mdx mouse TA injected by pAMICDYS (c, f) or 
pAVP22 -MICDYS (b, e) at 2 weeks (b, c) and 16 weeks (e, f) 
after injection, the right TA injected by PBS (d). The TA of 
C57BL/10 (a). Magnification: × 200.
Western blotting analysis indicated VP22 enhanced microd-ystrophin gene expression in TA of mdxFigure 3
Western blotting analysis indicated VP22 enhanced 
microdystrophin gene expression in TA of mdx. West-
ern blotting analysis of microdystrophin expression in mdx 
TA injected by pAMICDYS or pAVP22-MICDYS after 2 
weeks. The 175-kDa-microdystrophin bands appeared 
stronger in pAVP22-MICDYS- compared to pAMICDYS-
transduced mdx TA.
The number of centrally nucleated fibers in treated TA of mdxFigure 5
The number of centrally nucleated fibers in treated 
TA of mdx. Centrally nucleated fibers were counted in 
transverse H&E cryosections from treated mdx mice. The 
ratio of centrally nucleated fibers (%) is shown as means ± SE 
in TA muscle at post-injection 2 weeks (G) and 16 weeks 
(H). * p < 0.05 compared with mdx mice; + p < 0.05 com-
pared with pAMICDYS transfered mice.
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distribution in the abdominal cavity and the contractile 
function of the diaphragm muscle with mdx mouse
It has been reported that the protein transduction domain
(PTDs) of the TAT-protein could mediate delivery of the
biologically active fusion protein to all tissues in mice fol-
lowing intraperitoneal injection, portal vein injection, tail
vein injection and after oral administration [31]. To
observe whether VP22-mediated microdystrophin fusion
protein also could spread in vivo and ameliorate the func-
tional deficiencies of the diaphragm of mdx mice, the plas-
mids pAVP22, pAVP22-MICDYS or pAMICDYS were
injected intraperitoneally in 6–8 week old mdx mice. Two
weeks after injection, the expression of microdystrophin
proteins was detected in myocardium, quadriceps and
diaphragm muscles by immunohistochemistry. There
were almost no microdystrophin-positive fibers in myo-
cardium, quadriceps and diaphragm muscles after injec-
tion of pAVP22 or pAMICDYS, there were also no
microdystrophin-positive fibers in quadriceps after injec-
tion of pAVP22-MICDYS. However, some microdys-
trophin-positive fibers were easily detected in diaphragm
muscles (Fig. 6) and heart muscles (Fig. 7) after injection
of pAVP22-MICDYS. To demonstrate if a functional
recovery could be measured in the diaphragm muscle, the
isometric contractile properties of diaphragm muscles
were tested in vitro. Compared with muscles that were
transfected with pAVP22, pAMICDYS or treated by PBS,
VP22-microdystrophin expression led to better protection
against eccentric contraction-induced injury (Table 2).
Discussion
Presently, gene therapy research for DMD focus mostly on
viral or plasmid-mediated gene transfer methods.
Although viral vectors have a higher transduction effi-
ciency, they display several drawbacks, such as the limited
carrying capacity of adeno-associated viral vectors, and
the propensity of adenoviral, retroviral and herpes sim-
plex viral vectors to elicit a strong immune response
against either vector or transgene encoded proteins. Thus,
all viral vectors are biological agents that carry at least
some risk to patient safety. Compared to viral vectors,
plasmid-mediated gene transfer has several advantages
due to its simplicity, safety and reliability. Plasmid-medi-
ated DNA transfer has no significant side effects and the
highly purified, large-scale plasmid DNA can be easily
obtained and the quality of plasmid DNA can be easily
controlled [32]. Furthermore, DNA is much more stable
than viral vectors and can be refrigerated for long periods
of time. Exceptionally, it seems that skeletal muscles inter-
nalize plasmid DNA much more efficiently than other tis-
sues do [33]. Therefore, plasmid DNA therapy may be
Immunohistochemical staining of microdystrophin in myocar-diu  fr m mdx mouse injected intraperitoneally w th pAM-CDYS or pAVP22-MICDYSFigure 7
Immunohistochemical staining of microdystrophin in 
myocardium from mdx mouse injected intraperito-
neally with pAMICDYS or pAVP22-MICDYS. The 
myocardium with C57BL/10 mouse (A); the myocardium 
with mdx mouse treated by pAVP22-MICDYS (B); treated by 
pAMICDYS (C). Microdystrophin -positive fibers were only 
detected in groups injected by pAVP22-MICDYS, not in 
groups injected by pAMICDYS. Magnification: × 100.
Table 2: Functional effects of pAMICDYS and pAVP22-MICDYS for diaphragm muscles though intraperitoneal injection
C57BL/10 mdx pAVP22 pAMICDYS pAVP22-MICDYS
(n = 4) (n = 4) (n = 3) (n = 5) (n = 5)
BM (g) 20.3 ± 1.5 23.8 ± 1.6 22.5 ± 1.5 23.3 ± 1.3 21.8 ± 1.6
sP0 (KN/m2) 215 ± 6.3 90.8 ± 4.3 92.1 ± 5.1 98.7 ± 5.8 145.3 ± 6.9*
Values are means ± SEM; n, number of mice; BM, body mass; sPo, specific maximum isometric tetanic force.
* P < 0.05 versus untreated mdx and treated by pAMICDYS.
Immunohistochemical staining of microdystrophin in the dia-phragm muscle from mdx mouse injected intraperitoneally with pAMICDYS r pAVP22-MICDYSFigure 6
Immunohistochemical staining of microdystrophin in 
the diaphragm muscle from mdx mouse injected 
intraperitoneally with pAMICDYS or pAVP22-
MICDYS. The diaphragm muscle with C57BL/10 mouse (A); 
the diaphragm muscle with mdx mouse treated by pAVP22-
MICDYS (B); treated by pAMICDYS (C). Microdystrophin -
positive fibers were only detected in groups injected by 
pAVP22-MICDYS, not in groups injected by pAMICDYS. 
Magnification: × 100.Page 5 of 9
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viral vector mediated gene therapy. Unfortunately, the
transfection efficiency of plasmid DNA by intramuscular
injection is relatively low and transgene expression only
occurs within a few centimeters from the injection site.
In this study, the HSV-1 VP22 protein was capable of
mediating intercellular protein transport, significantly
enhancing the transduction efficiency of plasmid express-
ing microdystrophin. To assess the feasiblity of applica-
tion of VP22 in gene therapy of DMD, we first evaluated
the VP22 shuttle effect in 3T3 cells and C2C12 cells in
vitro. In imunofluorescence study, the VP22 fusion
increased microdystrophin accumulation in 3T3 cells and
transported microdystrophin into C2C12 cells. Following
intramuscularly injection of the VP22-microdystrophin
plasmid into the TA muscles of mdx mice, the VP22 fusion
increased both expression and distribution of the VP22-
microdystrophin fusion protein. Interestingly, microdys-
trophin mRNA was detected in some consecutive muscles
adjacent to injected TA such as gastrocnemius and soleus
muscles. One explanation is that the VP22 PTDs may carry
the micelles of plasmid pAVP22-MICDYS into neighbor-
ing cells. Alternatively, PTDs may directly carry DNA into
the neighboring cells. As a result, carried plasmid
pAVP22-MICDYS transcript microdystrophin mRNA.
However, naked plasmid DNA renders very low level of
gene delivery by direct i.m, electroporation should be
applied with i.m to enhance greatly the efficiency of VP22-
mediated gene therapy.
Due to the absence of dystrophin, DMD patients develop
progressive muscle degeneration in the diaphragm, which
often leads to respiratory failure and death. Therefore,
gene transfer into the diaphragm is important for the
treatment of DMD patients. Microdystrophin has been
shown to restore expression of the dystrophin-glycopro-
tein complex and improve sarcolemma integrity in the
mdx mouse heart [34] and diaphragm [11,30]. However,
delivery of the functional microdystrophin gene to dia-
phragm is a formidable problem. Although gene transfer
into the diaphragm is readily obtained by either direct
injection or pressure-mediated approach in experimental
mdx mice [35], it is not feasible to apply those methods to
patients. Protein transduction domains (PTD) can medi-
ate efficient transduction of all tissues in mice, even the
brain and skeletal muscle cells when administered by
intraperitoneal or intravenous injection [31,35-38]. For
example, intraperitoneal injection of a fusion protein
encoding the 116-kDa β-galactosidase fused to the TAT
PTD resulted in delivery of the biologically active fusion
protein to all tissues in mice, including the diaphragm
and the brain [31]. In the present study, expression of
microdystrophin, along with a partial functional recovery
of the diaphragm contractile properties was observed in
diaphragm and heart muscle after intraperitioneal injec-
tion of fusion protein plasmid. We found fusion with
VP22 could expand the distribution of the microdys-
trophin protein in the abdominal cavity and improved the
contractile function with diaphragm. Moreover, the VP22-
microdystrophin fusion protein could transport into heart
muscle through diaphragm. We did not detect fusion pro-
tein in the brain or other skeletal muscles, suggesting that
VP22 has only little capability to cross the barrier of blood
vessel. This deficit of VP22 may also be improved by using
a new type of PTD of VP22 with altered amino acid
sequence, or by using a different PTD as the carrying vec-
tor. Alternatively, the purified fusion protein can be
injected directly into the body though by intraperitoneal
or intravenous injection.
In the present study, microdystrophin gene was used as
the functional gene to correct the dystrophic phenotype in
muscles of mdx mice caused by the absence of full-length
dystrophin. However, the microdystrophin product is less
effective functionally at complementing dystrophin defi-
ciency than is the full-length cDNA, which is also a short-
coming of AAV-vector-mediated gene delivery for DMD.
Nevertheless, our results suggest that VP22 mediated plas-
mid gene transfer is a feasible gene therapy for DMD.
However, careful investigation of VP22 transport mecha-
nisms should be conducted before its application with
gene therapy since there is little know about the in vivo dis-
tribution and transport properties of VP22.
Although controversy remains about the trafficking
potential of VP22, we demonstrate the feasibility and effi-
ciency of VP22-mediated intercellular microdystrophin
protein delivery following in vitro and in vivo gene trans-
fection, suggesting that the VP22-mediated protein deliv-
ery system can be a useful tool to enhance the efficacy of
DMD gene therapy.
Conclusion
Overall, our results clearly demonstrate that the VP22-
microdystrophin fusion protein enhanced the expression
of microdystrophin in transfected 3T3 cells and trans-
ported into myoblast (C2C12) cells from 3T3 cells. More-
over, VP22 could carry microdystrophin to translocate
into neighboring muscle cells in dystrophin-deficient
(mdx) mice. These results document the efficiency of the
VP22-mediated intercellular protein delivery for potential
therapy of DMD and suggest that protein transduction
may be a potential and versatile tool to enhance the effects
of gene delivery for somatic gene therapy of DMD.
Methods
Vector construction
Full-length cDNA for HSV-VP22 was amplified by
polymerase chain reaction from plasmid pSINrep5-VP22Page 6 of 9
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ogy, Johns Hopkins Medical Institutions, Baltimore, Mar-
yland) and subcloned into the BamHI/NotI digested
multi-cloning site of pVAX1 expression vector (Invitro-
gen), named pAVP22. The microdystrophin cDNA (∆R4-
R23/∆CT) is a truncated version of the full-length dys-
trophin cDNA which was generated by introducing dele-
tions encoding repeats 4 though 23 within the rod
domain and the cterminal domain [30]. Full-length cDNA
for human microdystrophin gene was acqured from the
plasmid pBSK-MICRO digested with NotI to release the
3.75 kb fragment containing human microdystrophin
gene, and this piece was subcloned into the NotI sites of
pAVP22 (C-terminal fusion to VP22) and pVAX1 respec-
tively, named pAVP22-MICDYS and pAMICDYS, pVAX1
vectors are driven by the CMV enhancer/promoter.
Cell culture and transfection
Mouse embryo fibroblast 3T3 cell lines and mouse C2C12
myoblasts were maintained in a humidified incubator at
37°C and 5% CO2 in Dulbecco's modified Eagle medium
(DMEM) containing 10% fetal calf serum, 4.5 g/l glucose,
3.7 g/l NaHCO3, and 1% penicillin and streptomycin
(Gibco). The 3T3 cells were grown in six-well polystyrene
tissue culture dishes, after growen to more than
80%~90%, cells were individually infected with 3.0 µg of
expression plasmid DNA (pAVP22, pAMICDYS, pAVP22-
MICDYS) in OPTI-MEM using the Lipofectamine™ 2000
Transfection Reagent Kit (Invitrogen) according to the
manufacturer's specifications. Forty-eight hours after
transfection, the media supernatant was collected and fil-
tered, and then the media supernatant was transferred
onto the C2C12 myotubes. After transferred for 45 min,
the expression of microdystrophin was detected by immu-
nocytochemistry.
Immunofluorescence staining
Transfected cells were fixed with 4% paraformaldehyde/
PBS, followed by 100% methanol, and then rinsed twice
with PBS and blocked by 5% HS for 1 h. Next, the cells
were incubated overnight at 4°C with the primary anti-
bodies mouse anti-dystrophin (1:20, Amino Terminal,
Chemicon). After thee rinses with PBS, CY3-conjugated
goat abti-mouse IgG (1:200, sigma) was added as a sec-
ondary antibody, and the cells were incubated for 1 h at
room temperature. Finally, all cells were rinsed thee times
with PBS, cell nuclei were counterstained with 0.01% 4',
6-diamidino-2-phenylindole (DAPI) (Sigma) for 5 min,
and then viewed with a fluorescent microscope (Olympus
BX51). The microdystrophin-expressing positive cells
were counted and expressed as the average number of pos-
itive cells per 6-well plate.
Animal injection
The mdx mice used in this study were originally purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). The
colonies were subsequently established by in-house
breeding at the Laboratory Animal Center of Sun-Yet Uni-
versity and mice (including experimental mice and breed-
ing pairs) were housed in a specific-pathogen-free animal
facility. All animal experiments were accorded to Sun-Yet
University guidelines for animal care. All mdx mice were
injected at the age of 6–8 weeks with the plasmid DNA
(pAVP22-MICDYS, pAMICDYS) diluted in PBS (1 µg/µl)
though tow routes (i.m. and i.p.): 100 µl of plasmid DNA
was injected directly into the left TA muscles, as the con-
trol,100 µl PBS was injected directly into the right TA mus-
cles; 300 µl of plasmid DNA was injected though the
intraperitoneally injection (Along the diaphragm) respec-
tively. Before the injection, the mdx mice were anesthe-
tized by intraperitoneal injection of 1.2% Avertin (0.24
mg/g body weight). All tissues were harvested after differ-
ent time points of the injection with plasmid DNA. The
mice were euthanized by an overdose of pentobarbital, all
tissue samples were snap-frozen in liquid nitrogen and
processed for subsequent immunocytochemical, molecu-
lar detection.
Measurement of diaphragm muscle contractile properties
After the mice were killed by an overdose of pentobarbi-
tal, a strip of the ventral part of the costal diaphragm with
the surrounding rib cage was carefully dissected out from
the muscle in situ and immediately placed in the oxygen-
ated Ringer's solution (120 mM NaCl, 5.0 mM KCl,1.0
mM CaCl2, 1.0 mM KH2PO4, 1.0 mM MgSO2, 10.0 mM
glucose, and 10.0 mM HEPES, corrected to a pH of 7.40).
And then the freshly diaphragm strip was rapidly
mounted vertically in a tissue chamber(HW-400SE,
Co.ltd.TaiMeng Technology, China) filled with a Ringer's
solution perfused with 95%O2:5%CO2. and maintained
at 25°C [39]. The costal end of the diaphragm strip was
held in a clip at the bottom of the chamber, whereas the
central tendon end was maintained with a second clip
which was attached to an electromagnetic force-trans-
ducer device (BL-420E+, Co. Ltd. TaiMeng Technology,
China). After a 20-min equilibration period, we adjusted
the muscle strip to optimal length L0 (The muscle length
that allowed maximal twitch force to be achieved was
defined as L0), and then the muscle was supramaximally
stimulated via two platinum electrodes arranged longitu-
dinally on either side of the muscle, which were attached
to a a square wave pulse stimulator BL-420E+ Stimulator
(Co. Ltd. TaiMeng Technology, China). A force frequency
curve was determined by stimulating muscle strips at
10,20,40,60,80, 100,120,140 and 160 Hz (1-ms pulse
duration, 330-ms train duration, 10 per minute). The
peak force generated by this protocol was used to calculate
the maximum tetanic force. Stimulations were controlled,Page 7 of 9
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tom software developed in Co. Ltd. TaiMeng Technology
(BL-420E+ experimental system with the function of biol-
ogy). Specific twitch and tetanic force normalized to mus-
cle CSA (kN/m2) were calculated according to the
following equation: CSA = (muscle mass, g)/[(optimal
fiber length, cm) × (muscle density, g/cm3)]. A muscle
density estimated at 1.06 g/cm [40]. All measurements
were performed on treated and untreated diaphragm
strips of mdx mice as well as in untreated diaphragm strips
obtained from wild-type C57/BL10 mice of the same age.
HE staining and central nucleation quantification
TA muscles samples were snap frozen in liquid nitrogen-
cooled isopentane and then made the frozen sections
stored in -80°C. Doing the HE staining to the ice slice of
the muscular tissue of experimental mice. The percentage
of centrally nucleated myofibers in the mdx mouse TA
muscle was determined by manually counting the total
number of myofibers and the total number of myofibers
carrying centrally located nuclei in a 6 µm HE-stained sec-
tion with an electronic colony counter. Equal or more
than four representative muscle sections were quantified
for each muscle sample. Calculating the percentage of cen-
tral nucleated fibers in whole observation fibers in 5 con-
tinuous scopes. The percentage of central nucleation was
calculated with the formula % central nucleation = (total
number of myofibers carrying centrally located nuclei)/
(total number of myofibers).
Indirect immunofluorescence detection of 
microdystrophin gene expression
Cryostat sections (6 µm) were prepared from the snap fro-
zen muscle samples. Slides were blocked with PBS con-
taining 10% normal goat serum for 1 h. Subsequently
sections were incubated with anti-dystrophin antibody, a
mouse monoclonal antibody directed against a amino-
terminal polypeptide fragment of human dystrophin
(1:20, Chemicon) at 4°C for over night. The secondary
antibody, FITC-conjugated polyclonal antibody goat-ant-
mice (1:200, Sigma) were applied for 1 h. The sections
were viewed with a fluorescent microscope. The microdys-
trophin expressing positive fibers were counted and
expressed as the average number of positive fibers per
muscle cross-section. At least four sections were counted
for each muscle. The positive stain fibers were observed
for successive 10 visual fields with fluorescent micro-
scope. Count the percentage of microdystrophin positive
fibers in the whole observing fibers and take the pictures
to these fibers. Muscle cell nuclei were counterstained
with 0.01% 4', 6-diamidino-2-phenylindole (DAPI)
(Sigma) for 5 min. Photographs were taken with an Olym-
pus IX71 fluorescent microscope.
Western blot analysis
Total cellular protein was extracted with a reducing sam-
ple buffer (10% SDS, 70 mM Tris-HCl, pH 6.8, 5% b-mer-
captoethanol, and 10 mM EDTA) from the tibialis
anterior (TA) muscle. The protein concentration was
determined by Bio-Rad protein assay. Protein/lane was
separated on a 6% SDS-polyacrylamide gel and electri-
cally transferred to a PVDF membrane (Millipore). After
blocking with 3% skim milk, the blot was incubated with
a mouse anti-dystrophin (amino terminal) monoclonal
antibody (1:30 dilution, Chemicon). After washing with
TBST, the blot was incubated with a 1:5000 dilution of
HRP-conjugated rabbit anti-mouse IgG1 antibody
(Chemicon). The signal was detected by using the
enhanced chemiluminescence method (Hyperfilm ECL;
Amersham Pharmacia Biotech, UK).
Statistical analyses
Values in the text and tables are reported as mean ± SEM.
Variables were compared between experimental groups
using Student's t test. Differences between groups were
considered significant when P was < 0.05.
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